| INTRODUC TI ON
Type 2 diabetes (T2D) is a chronic condition frequently characterized by progressive worsening of glycaemic control. The long-term positive effects of early interventions to correct hyperglycaemia have been recognized since the publication of the 10-year followup of the United Kingdom Prospective Diabetes Study (UKPDS).
1
Among patients with newly diagnosed T2D who were randomized to intensive therapy (insulin, sulphonylurea, or metformin) or dietary restriction, long-term benefits of intensive therapy in terms of microvascular risk (vitreous haemorrhage, retinal photocoagulation, or renal failure), myocardial infarction, and death were evident even though differences in glycaemic control between groups quickly disappeared after trial end. More recently, in the ORIGIN trial, patients with T2D who were assigned to early intervention with insulin glargine were more likely to maintain glycaemic control for 5 years than those randomized to standard care.
2
Many patients with T2D ultimately require insulin therapy for adequate control of hyperglycaemia. However, despite the proven clinical benefits of insulin for patients with T2D, patients and physicians are often reluctant to initiate insulin-principally due to an interplay of attitudes related to injectable therapy, treatment complexity, and negative perceptions toward the meaning and consequences of insulin initiation. [3] [4] [5] [6] [7] [8] Real-world data to illustrate the effect of duration of hyperglycaemia and the extent of clinical inertia, including the effects of glycaemic control, in patients with T2D would be useful. The aim of the current study was to examine the effects of different durations of hyperglycaemia on glycaemic control clinical treatment outcomes following initiation of basal insulin (BI).
| MATERIAL S AND ME THODS

| Study data source
This retrospective analysis used data derived from electronic medical records (EMRs) within the GE Centricity platform. GE Centricity is a large platform used by 35 000 clinicians to manage data from over 17 million patients across the USA. 9 The database comprises a broad range of clinical and demographic information. Further, the data are captured longitudinally, so long-term outcomes can be studied.
| Study population
Data were selected from patients with ≥1 diagnosis of T2D
(ICD-9-CM codes 250.x0 or 250.x2) between January 1, 2007, and 
| Outcome measures
The following outcomes were studied for eligible patients in each of the four cohorts: A1C, weight, BMI, blood pressure, and diabetes medications. A1C data reported were: average A1C during the Weight, BMI, and blood pressure data were reported at baseline (last value before the index date) and 12-month follow-up (last value up to 15 months postindex date for patients who were persistent to BI for ≥360 days. Patients with at least one T2D diagnosis 
| Data analyses
| Basal insulin persistence
In the overall cohort, 94.0% of patients were persistent to BI for ≥90 days in the first 3 months, 90.0% for ≥180 days in the first 6 months, 86.9% for ≥270 days in the first 9 months, and 85.8% Charlson comorbidity index score 87.2%, and 87.6%, respectively, were persistent for ≥360-day follow-up in the <6-, 6-to <12-, 12-to <18-, and 18-to 24-month cohorts).
| A1C control
During the 1-2 years preindex date, mean A1C was higher in the 12-to <18-and 18-to 24-month cohorts ( Figure 3A) . By the index date, mean A1C was similar across the <6-, 12-to <18-, and 18-to 24-month cohorts, but slightly lower in the 6-to <12-month cohort ( Figure 3A) .
Patients in the <6-month cohort demonstrated the best glycaemic control at all time points during follow-up, followed by those in the 6-to <12-, 12-to <18-, and 18-to 24-month cohorts (A1C 8.0%, 8.2%, 8.5% and 8.6%, respectively; Figure 3A ). Thus, a trend of rising A1C was observed with longer duration of hyperglycaemia. Similarly, achievement of A1C <7.0% during follow-up increased in line with decreased duration of time with uncontrolled A1C preindex date (29.6%, 20.0%, 14.6%, and 11.5%, respectively, in the <6-, 6-to <12-, 12-to <18-, and 18-to 24-month cohorts; Figure 3B ).
| Weight, BMI, and blood pressure
Mean weight increased slightly between baseline and follow-up in all cohorts ( Figure 4A ). Mean ± SD weight gain among those with both baseline and follow-up weight measurements (n = 22 507) was similar across cohorts (1.4 ± 23.7, 1.1 ± 23.8, 1.5 ± 25.0, and 0.8 ± 24.0 kg, respectively, for the <6-, 6-to <12-, 12-to <18-, and 18-to 24-month cohorts). BMI (mean ± SD) was similar at baseline and follow-up across cohorts ( Figure 4B ). Among patients with both baseline and followup BMI measurements (n = 26 177), mean ± SD BMI increase was 0.1 ± 3.2 kg/m 2 . At follow-up, 64.7% of patients were obese, 21.2% overweight, and 14.1% in healthy range.
F I G U R E 3
The apparent discrepancy between small weight gain and similar BMI may be due to missing data. Although 92% patients had a follow-up BMI (and 83% had a baseline BMI), only 74.34 had a baseline weight (and 70% a follow-up weight).
Among patients with systolic blood pressure readings at baseline and follow-up (n = 30 095), the mean ± SD increase was 0.1 ± 92.6 mm Hg; for diastolic blood pressure (n = 30 125), the mean decrease was 0.8 ± 16.3 mm Hg. There was little clinically relevant difference between cohorts.
| Oral antidiabetes treatment during follow-up
The mean numbers of oral antidiabetes medications received in the baseline period were 2.10, 2.32, 2.40, and 2.46, respectively, in the <6-, 6-to <12-, 12-to <18-, and 18-to 24-month cohorts. Few patients initiated additional antidiabetes drugs during follow-up, but treatment initiation was slightly more common in the <6-month cohort ( Figure 2C ).
| D ISCUSS I ON
In this retrospective cohort analysis, in patients with A1C >7% at baseline, shorter time spent with uncontrolled A1C before the initia- Overall, it seems that starting insulin before A1C becomes too high (≥8.0%) and in a timely manner after A1C control is lost is likely to result in better glycaemic control. This may be because patients with a longer duration of uncontrolled A1C before BI initiation may have suffered more glucotoxicity, leading to increased loss of β-cell mass. 13 This could potentially affect target A1C attainment or maintenance of glycaemic control-particularly in those patients receiving insulin secretagogues as next intensification. Numerous studies have established that after treatment intensification, delays have been shown to be associated with poorer response to the added therapy. Thus, delaying treatment intensification exposes patients to avoidable hyperglycaemia both during and after the delays.
14-17
These results highlight the benefit of early initiation of intensification therapy in patients not at target, and demonstrate that prolonged hyperglycaemia may be associated with decreased ability to reach target.
It should be noted that glycaemic goal attainment was quite poor (12%-30%) in all cohorts in the current study-this is in line with a previous US claims database analysis by Dalal et al, 18 in which 27%
of patients who initiated BI reached A1C <7.0%. It is also in line with National Health and Nutrition Examination Surveys (NHANES) data, in which 30% of diabetes patients on insulin attained A1C <7.0%.
19
It is also notable that A1C reductions observed in the current study occurred in the first 3-6 months following BI initiation, after which time mean A1C levels plateaued. Similar results have recently been reported among a cohort of real-world patients with T2D initiating BI.
20
Both poor A1C target attainment and A1C plateau may be due to insufficient insulin intensification. This reluctance to intensify insulin regimens may be due to factors including fear of hypoglycaemia, weight gain, burdensome regimens, or cost. 21 In this regard, currently available second-generation BIs have sought to reduce hypoglycaemia risk without compromising A1C reduction; 22, 23 however, it remains to be determined whether these novel insulins (eg, insulin glargine 300 units/mL and insulin degludec) will overcome such reluctance to intensify insulin therapy. Although mean baseline BMI was relatively consistent across cohorts, patients in the two shorter-duration cohorts tended to have a slightly higher mean baseline weight vs those in the longer-duration cohorts. Among patients with both baseline and follow-up BMI data, mean changes in BMI were very small in all four cohorts. Among patients with both baseline and follow-up weight measurements, mean ± SD weight gain was 1.2 ± 24.0 kg. Clearly, weight change varied widely among patients, but weight gain after initiating insulin is as would be expected. 25 BMI data show that 67.8% of our study population was obese at BI initiation. Newer fixed-ratio coformulation therapies using BI and glucagon-like peptide-1 receptor agonists can offer an alternative therapy for targeting glycaemic control while mitigating or reducing weight gain, which may be of use in this population.
Patients in the shortest-duration cohort received fewer noninsulin diabetes drugs during the 2 years before BI initiation, presumably because diabetes was diagnosed during this time for some patients. This is supported by the fact that only 39.5% of patients in the <6-month cohort had an available A1C measurement during the 1-2 years before their index date, compared with 56.2%, 100%, and 100%, respectively, in the 6-to <12-, 12-to <18-, and 18-to 24-month cohorts.
| Limitations
As with all retrospective observational studies, where randomization is not undertaken, there is a risk of selection bias. Further, as Finally, the collection of data relating to insulin dose at index date and again at follow-up would have been useful in exploring the association between diabetes management, duration of uncontrolled A1C, and attainment of glycaemic targets.
| CON CLUS ION
Our retrospective, real-world data analyses suggest that delaying treatment intensification (BI initiation in this study) increases the risk of not meeting glycaemic targets; in addition, there is a trend of rising A1C after BI initiation in patients with longer-duration uncontrolled A1C. This does not change significantly, even with continued treatment with BI beyond 6 months up to 1 year. Thus, uncontrolled A1C duration may be an important indicator to the clinician and could serve as a call to action to review the clinical care and need for intensification of therapy. These results point towards the need for earlier therapy intensification in this population. Moreover, our observation that attainment of A1C <7.0% during follow-up increased in line with decreased duration of time with uncontrolled A1C before starting BI highlights that glycaemic control does not change much after 6 months; thus, other intensification therapies are needed.
While patients have uncontrolled A1C, they are at increased risk of micro-and macrovascular complications as well as disease progression. Such patients would benefit from initiating treatments that can improve glycaemic control without a high risk of hypoglycaemia or weight gain. Solutions, which received funding from Sanofi. DR is a member of advisory boards/speaker during symposia for AstraZeneca, Janssen, Lilly, Novartis, Novo Nordisk, Sanofi.
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